LONDON, March 19, 2014 /PRNewswire/ --
On Tuesday, March 18, 2014, the
NASDAQ Composite finished at 4,333.31, up 1.25%. The Dow Jones
Industrial Average closed the session at 16,336.19, up 0.55% and
the S&P 500 ended the day at 1,872.25, higher by 0.72%. The
gains were broad based with 9 of 10 sectors ended the session in
positive. The S&P 500 Health Care Sector Index closed the day
at 688.96, up 1.17%, and the same has gained 1.57% in the previous
three trading sessions. Investor-Edge has initiated coverage on the
following equities: Bristol-Myers Squibb Co. (NYSE: BMY), Johnson
& Johnson (NYSE: JNJ), Merck & Co. Inc. (NYSE: MRK) and Eli
Lilly & Co. (NYSE: LLY). Free technical research on BMY, JNJ,
MRK and LLY can be downloaded upon signing up at:
http://www.investor-edge.com/339-register
On Tuesday, shares in Bristol-Myers Squibb Co. edged 0.02% higher,
finishing the session at $54.73. The
stock recorded a trading volume of 5.29 million shares as compared
to a three months average volume of 8.64 million shares. The stock
fluctuated between $54.28 and $54.93
during the session. Shares of the company traded at a PE ratio of
32.63. Bristol-Myers Squibb Co.'s shares have gained 1.02% in the
previous three trading sessions, 0.18% in the last one month and
2.97% on YTD basis. The company's shares are trading above its
50-day and 200-day moving averages. Bristol-Myers Squibb Co.'s
50-day moving average of $53.35 is
above the 200-day moving average of $48.82. Moreover, the stock is trading at the
Relative Strength Index (RSI) of 53.29. Sign up today to read free
research on BMY at:
http://www.investor-edge.com/339-BMY-19Mar2014.pdf
Shares in Johnson & Johnson recorded a trading of 5.86 million
shares, as compared with a three months average volume of 8.10
million shares. The stock ended the day at $93.94, up 0.01% and at an intraday range of
$93.48 and $94.24. Shares of the company traded at a PE
ratio of 17.15. Johnson & Johnson's shares have advanced 1.01%
in the previous three trading sessions, 1.92% in the last one month
and 2.57% on YTD basis. The company's stock is trading above its
50-day and 200-day moving averages. Johnson & Johnson's 50-day
moving average of $92.08 is above the
200-day moving average of $90.58.
Furthermore, the stock is trading at the Relative Strength Index
(RSI) of 60.42. Sign up today to read free research on JNJ at:
http://www.investor-edge.com/339-JNJ-19Mar2014.pdf
On Tuesday, shares in Merck & Co Inc. closed the day at
$56.36, up 0.18%. A total of 7.04
million shares were traded, which is below the three months average
volume of 12.32 million. The company's shares oscillated between
$56.16 and $56.56 during the trading
session. Merck & Co Inc.'s shares have gained 1.02% in the
previous three trading session, 1.20% in the last one month, and
12.61% on YTD basis. The company's shares are trading above their
50-day and 200-day moving averages. Merck & Co Inc.'s 50-day
moving average of $54.09 is above the
200-day moving average of $49.41.
Furthermore, the stock is trading at the Relative Strength Index
(RSI) of 55.01. Sign up today to read free research on MRK at:
http://www.investor-edge.com/339-MRK-19Mar2014.pdf
Eli Lilly & Co.'s stock recorded a trading volume of 4.06
million shares, as compared with a three months average volume of
5.50 million shares. The stock finished the day at $59.40, up 0.90% after trading between
$58.81 and $59.70. Shares of the company traded at a PE
ratio of 13.44. Eli Lilly & Co. shares have advanced 1.82% in
the previous three trading sessions, 7.51% in the last one month
and 16.47% on YTD basis. The company's shares are trading above its
50-day and 200-day moving averages. Eli Lilly & Co.'s 50-day
moving average of $55.45 is above the
200-day moving average of $52.28.
Additionally, shares of the company are trading at the Relative
Strength Index (RSI) of 60.29. Sign up today to read free research
on LLY at:
http://www.investor-edge.com/339-LLY-19Mar2014.pdf
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
3. This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at
compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage
on your company? Send us a full investors' package to research [at]
http://www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis.
This document, article or report is prepared and authored by
Investor-edge. An outsourced research services provider represented
by Nidhi Vatsal, CFA, has only reviewed the information provided by
Investor-edge in this article or report according to the Procedures
outlined by Investor-edge. Investor-edge is not entitled to veto or
interfere in the application of such procedures by the outsourced
provider to the articles, documents or reports, as the case may
be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or
otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Investor-edge
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Investor-edge expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Investor-edge does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Investor-Edge